გამოგვყევი
GE
GE

Life4me+-ის ერთ-ერთი მთავარი მიზანია აივ, სხვა სგგი, ჰეპატიტი C და ტუბერკულოზის ახალი შემთხვევების პრევენცია.

აპლიკაცია ეხმარება აივ დადებით პირებს ექიმებთან ანონიმური კომუნიკაციის დამყარებაში. ეს ყველაფერი დაგეხმარებათ ორგანიზება გაუკეთოთ მედიკამენტების მიღების განრიგს და დააყენოთ ფარული და პერსონალიზებული შეხსენებები.

ყველა სიახლე

არქივი

✕
20 აპრილი 2021
2644
Benefits of continuing to provide HIV services outweigh the risk of COVID-19 transmission by 100-to-1, say WHO

Benefits of continuing to provide HIV services outweigh the risk of COVID-19 transmission by 100-to-1, say WHO

The World Health Organisation has said that disruption to HIV services, which has been as high as 75% in some regions, must stop so that people can continue to access life-saving HIV treatment. Working with UNAIDS the WHO have been using mathematical modelling to establish ...
20 აპრილი 2021
2654
Updated guidelines for the treatment of HIV in children for the USA and Russia

Updated guidelines for the treatment of HIV in children for the USA and Russia

In the first quarter of 2021 both the USA and Russia have updated their guidelines on the treatment and monitoring of children and adolescents with HIV. The changes include the recommended treatment regimens, as well as clinical and laboratory monitoring. In January 2021, ...
24 მარტი 2021
3077
Lower CD4 counts linked with higher cancer risks in people living with HIV in South Africa

Lower CD4 counts linked with higher cancer risks in people living with HIV in South Africa

A report in Clinical Infectious Diseases has said that immune suppression is linked with an increased risk of numerous cancers amongst people living with HIV, according to data collected and analysed in South Africa. The study’s authors found links between a low CD4 count ...
24 მარტი 2021
3824
Chinese HIV drug, Aikening, gets first approval outside China

Chinese HIV drug, Aikening, gets first approval outside China

The Republic of Ecuador has become the first country outside of China to authorise the sale and use of a HIV drug developed in China by Frontier Biotech. Aikening (Albuvirtide 160mg) is a new long-acting injectable fusion inhibitor designed to be administered once a week. ...
22 მარტი 2021
2860
AstraZeneca applies for FDA authorisation after study shows vaccine to be safe and effective

AstraZeneca applies for FDA authorisation after study shows vaccine to be safe and effective

The AstraZeneca vaccine, developed in collaboration with Oxford University, is ‘highly effective’ at preventing COVID-19 in all age groups says the company following a Phase III trial in the US, Chile and Peru. The trial, run by Columbia University and the University ...
22 მარტი 2021
2673
Long-acting injectable ART is effective for people over 50

Long-acting injectable ART is effective for people over 50

A long-acting injectable antiretroviral treatment (ART), comprised of cabotegravir and rilpivirine, has shown similar levels of efficacy, safety and tolerability in study participants aged over 50 as in those under 50, according to data presented at Conference on Retroviruses ...
21 მარტი 2021
2737
WHO publishes new guidelines for HIV treatment and care

WHO publishes new guidelines for HIV treatment and care

As the world continues to tackle the ongoing COVID-19 pandemic the World Health Organisation (WHO) is concerned about maintaining the pace and progress in treating and managing HIV. The new recommendations outline key new actions that countries can take to improve the ...
21 მარტი 2021
2861
TAF and Integrase Inhibitors shown to promote weight gain in people living with HIV

TAF and Integrase Inhibitors shown to promote weight gain in people living with HIV

Tenofovir alafenamide (TAF) promotes weight gain in people who switch HIV treatment regimen according to results from three studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2021). The largest study on weight gain so far included a ...
21 მარტი 2021
2861
Could four-day ART be just as effective as daily ART?

Could four-day ART be just as effective as daily ART?

A four-day on and three-day off HIV antiretroviral treatment (ART) regimen could be just as effective as a daily regimen according to data presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2021). Scientists presented data from the QUATOR study ...
21 მარტი 2021
2940
The ‘Sao Paulo Patient’ restarts treatment as HIV returns

The ‘Sao Paulo Patient’ restarts treatment as HIV returns

A patient from São Paulo, Brazil, had been maintaining an undetectable viral load for 72 weeks after stopping his antiretroviral therapy (ART), however it was reported at the Conference on Retroviruses and Opportunistic Infections (CROI 2021) that his viral load had increased ...
ჩვენ ვიყენებთ ქუქის, რათა გავაუმჯობესოთ თქვენ მიერ საიტის მოხმარება
ვებ-გვერდზე ნებისმიერ ღილაკზე დაჭერით თქვენ გვაძლევთ უფლებას, რომ გამოვიყენოთ თქვენი cookies.